Section
A large-scale prospective study in JAMA Neurology identifies circumferential aneurysm wall enhancement (AWE) as a potent independent predictor of intracranial aneurysm growth or rupture, offering a critical radiological biomarker for clinic
Long-term data from the ATTENTION trial reveal that endovascular thrombectomy significantly improves functional outcomes and survival at three years for patients with basilar artery occlusion, establishing it as a durable standard of care.
A multicenter study identifies high-sensitivity troponin I kinetics as a diagnostic marker for hemorrhagic myocardial infarction, linking this reperfusion injury to a nearly threefold increase in the risk of in-hospital mortality following
A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic c
A large-scale multicenter study identifies unique multivariate patterns of peripheral inflammation and brain structure that differentiate early-stage depression and psychosis, highlighting the influence of childhood trauma and cognitive per
The multicenter GLIAA trial demonstrated that FET-PET-guided target volume delineation for re-irradiation does not provide a progression-free survival benefit over standard contrast-enhanced T1-weighted MRI in patients with recurrent gliobl
A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course
Long-term data show RAPID MRI-directed pathway safely avoids unnecessary biopsies while maintaining low rates of clinically significant prostate cancer.
Longitudinal tau-PET accumulation follows distinct regional patterns across biological AD stages; aligning trial inclusion and outcome ROIs to baseline tau stage can substantially reduce sample sizes and improve power for disease-modifying
In a randomized phase 2 trial, proton craniospinal irradiation (pCSI) significantly improved central nervous system progression‑free survival and overall survival versus involved‑field photon radiotherapy in patients with leptomeningeal met
This review synthesizes recent large-scale multi-cohort studies revealing white matter microstructural abnormalities—especially free water increases—in limbic tracts as critical markers of cognitive decline in aging and Alzheimer’s di
In the DISCHARGE randomized trial prespecified secondary analysis, CT-first and ICA-first strategies produced similar long-term quality-of-life and angina outcomes in intermediate-risk stable chest pain patients over a median 3.5 years; imp
In a large single‑institution cohort of oropharyngeal squamous cell carcinoma, proton therapy was associated with a higher 3‑year rate of osteoradionecrosis than IMRT (6.4% vs 2.7%), though severe ORN remained uncommon.
A large single-center cohort (n=7,622) shows 12.6% of head and neck cancer patients develop severe (≥RTOG grade 3) radiation-related late toxicities; modifiable factors and specialized multidisciplinary late-effects care may reduce risk and
A large Mayo Clinic Study of Aging analysis shows lifetime and 10‑year absolute risk of MCI and dementia rise monotonically with amyloid PET centiloid values, modified by age, sex, and APOE ε4 status; out‑of‑study ascertainment substantiall
A large Chinese registry-based target-trial emulation found interventional therapy for unruptured brain AVMs reduced 5- and 10-year hemorrhage-free survival compared with conservative management, with benefits concentrated in low-grade, com
A phase 1 trial reports tolerable single‑fraction preoperative stereotactic partial‑breast irradiation (30–38 Gy) with low toxicity, preserved cosmesis, and high pathologic complete response rates when surgery was delayed beyond ~9 months o
A Medicare claims analysis found that 15% of balloon sinus dilation (BSD) procedures lacked a CT within one year; 31.8% of otolaryngologists were outliers, with a small subset accounting for the majority of missed imaging—highlighting gaps
The INTERACT-ION phase 2 trial reports that induction ezabenlimab with modified DCF followed by biomarker-guided, involved-node radiotherapy produced high clinical complete response rates (overall 77.8%) with a manageable safety profile in
A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.
